744315
Last Update Posted: 2008-10-15
Recruiting status is unknown
All Genders accepted | Under 75 Years |
20 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Induced Angiogenesis by Genic Therapy in Advanced Ischemic Cardiomyopathy
Human Vascular Endothelial Grown Factor 165 (hVEGF165) administration is promising therapy induces a new vessels, arterioles and capillaries in regions whose revascularization surgery is not possible by direct or by percutaneous angioplasty. This study aims to evaluate the clinical effects and safety of gene therapy with hVEGF165 in patients with advanced coronary artery disease.
Eligibility
Relevant conditions:
Ischemic Cardiopathy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Imarilde Giusti, MD
pesquisa@cardiologia.org.br
555132192802
Data sourced from ClinicalTrials.gov